nterferon remains a benchmark therapy for CHB [13]. We further investigated whether pSecTagB-IFN-α could play anti-HBV role by an autocrine hIFN-α pathway. HepG2.2.15 cells were transfected with pSecTagB-IFN-α vector or empty vector, and then HBV replication level was evaluated. As shown in Figure 2A,B the mRNA levels of HBs and HBc was decreased to 64% and 68%, respectively, 24 h post of treatment; HBV DNA load (Figure 2C) and the contents of HBsAg and HBeAg (Figure 2D,E) were also reduced significantly by pSecTagB-IFN-α transfection. These results indicated that pSecTagB-IFN-α vector could suppress HBV life activities.